Cocrystal Pharma, Inc.COCPNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank51
3Y CAGR-77.3%
5Y CAGR-47.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-77.3%/yr
Quarterly compound
5Y CAGR
-47.0%/yr
Recent deceleration
Percentile
P51
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 0.90% |
| Q2 2025 | 9.95% |
| Q1 2025 | 27.52% |
| Q4 2024 | 35.94% |
| Q3 2024 | 7.45% |
| Q2 2024 | -31.02% |
| Q1 2024 | 10.89% |
| Q4 2023 | -5.02% |
| Q3 2023 | -2.40% |
| Q2 2023 | 15.10% |
| Q1 2023 | -13.53% |
| Q4 2022 | 20.93% |
| Q3 2022 | 76.69% |
| Q2 2022 | -480.93% |
| Q1 2022 | -13.59% |
| Q4 2021 | 6.35% |
| Q3 2021 | -3.27% |
| Q2 2021 | -39.81% |
| Q1 2021 | -86.77% |
| Q4 2020 | 45.88% |
| Q3 2020 | 21.48% |
| Q2 2020 | -75.93% |
| Q1 2020 | 95.91% |
| Q4 2019 | -2550.72% |
| Q3 2019 | -16.65% |
| Q2 2019 | -153.88% |
| Q1 2019 | 105.11% |
| Q4 2018 | -2227.53% |
| Q3 2018 | -13.46% |
| Q2 2018 | -3.14% |
| Q1 2018 | -12.83% |
| Q4 2017 | 13.18% |
| Q3 2017 | -75.83% |
| Q2 2017 | 61.55% |
| Q1 2017 | 96.69% |
| Q4 2016 | -4883.42% |
| Q3 2016 | 54.95% |
| Q2 2016 | 21.18% |
| Q1 2016 | 87.98% |
| Q4 2015 | -1136.02% |